The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2022 | Clinical trials investigating immunotherapy for gastric cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Chiba, Japan, talks on how to improve outcomes for patients with gastric cancer who are resistant to checkpoint inhibitors. Dr Shitara discusses a variety of clinical trials investigating the use of checkpoint inhibitors in different subgroups of patients with gastric cancer. Predictive biomarkers are a key tool for improving outcomes in this area and several are currently under investigation. There are also a range of therapeutic possibilities being looked into, such as the use of tyrosine kinase inhibitors (TKIs) and CAR-T cell therapies. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
A position of a board member or advisor: Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, Merck Pharmaceutical, Taiho Pharmaceutical, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan, and Janssen
Honoraria for lectures: Takeda, Janssen and Bristol-Myers Squibb
Clinical research grants: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Medi Science, Eisai and Amgen
